Semaglutide Patent Expires March 2026, Indian Generics Set to Launch

The patent for semaglutide expires on March 20, 2026, opening the door for generic manufacturers to enter the anti-obesity and anti-diabetic drug markets. Indian pharmaceutical companies are preparing to launch generic versions starting March 21, 2026.

Several Indian pharmaceutical giants have secured regulatory approvals and are positioning for early market entry. Sun Pharma plans a day-one market entry with its brand Noveltreat, leveraging its leadership in cardiometabolic therapies. Dr. Reddy's Laboratories has received approval for a generic Ozempic for type 2 diabetes and aims to launch 12 million pens in its first year. Zydus Lifesciences is developing a differentiated injectable version. Eris Lifesciences and Natco Pharma have formed a strategic alliance in anticipation of the market surge.

Analysts project that generic semaglutide formulations will be priced significantly lower, initially 30-50% less than innovator brands, with potential price reductions reaching 70-75% over time. This price erosion is expected to democratize access, moving treatments from a luxury for the affluent to a viable option for a broader population.

The Indian anti-obesity market, currently valued at approximately ₹1,400 crore, is forecast to double within the next year and potentially grow tenfold over the coming years due to intensified competition and increased adoption. The GLP-1 segment alone has already surpassed ₹1,000 crore in annual sales in India.

Sun Pharma shows operational metrics including ROCE of 18.97% and ROE of 15.66%, but its P/E ratio is elevated, ranging from 33.9 to 103.36 as of early 2026, with reported poor 3-year revenue growth. Dr. Reddy's Laboratories trades at a P/E of approximately 18.36. Zydus Lifesciences has a P/E around 19.55, with strong revenue and profit growth and a healthy ROE of 31.29%. Natco Pharma exhibits one of the lowest P/E ratios at 10.36, coupled with strong profit growth and being nearly debt-free. Cipla maintains a P/E of around 23.57, while Eris Lifesciences presents a higher valuation with a P/E exceeding 40 and even 60, alongside concerns about poor profit growth over the last three years.

The Indian pharmaceutical sector overall is projected for 7-9% growth in FY26, driven by domestic demand and European markets, though the US market faces headwinds from pricing pressures.

The impending price war poses significant risks to profitability. The intense competition could lead to margin compression across the board, especially for companies that fail to achieve economies of scale or differentiate their offerings beyond basic generics. The rush to capture market share may also lead to aggressive spending on sales forces and marketing, potentially offsetting some of the cost advantages gained from generic production.